deltatrials
Completed PHASE3 NCT00481767

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.

Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine GSK580299 in Healthy Female Subjects Aged 10-25 Years.

Sponsor: GlaxoSmithKline

Conditions Human Papillomavirus (HPV) Infection
Interventions Cervarix Placebo Al(OH)3
Updated 9 times since 2017 Last updated: Oct 26, 2020 Started: Oct 1, 2007 Primary completion: Feb 25, 2010 Completion: Jul 26, 2010

This PHASE3 trial investigates Human Papillomavirus (HPV) Infection and is currently completed. GlaxoSmithKline leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE3

  5. Aug 2018 — Dec 2020 [monthly]

    Completed PHASE3

▶ Show 4 earlier versions

  1. Jun 2018 — Aug 2018 [monthly]

    Completed PHASE3

  2. Apr 2018 — Jun 2018 [monthly]

    Completed PHASE3

  3. Feb 2017 — Apr 2018 [monthly]

    Completed PHASE3

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Dakar, Senegal
  • • Mwanza, Tanzania